XML 94 R65.htm IDEA: XBRL DOCUMENT v3.24.1
Income and Expenses - Additional Information (Details) - EUR (€)
€ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disclosure Of Income And Expenses [Line Items]      
Decrease cost of sales € (2,395.2)    
Cost of sales (as a percent) (80.00%)    
Cost of sales € 599.8 € 2,995.0 € 2,911.5
Inventories 357.7 439.6  
Increase of research and development expense € 246.1    
Research and development expense (as a percent) 16.00%    
Research and development expenses € 1,783.1 1,537.0 949.2
Increase of sales and marketing expense € 3.2    
Sales and marketing expense (as a percent) 5.00%    
Sales and marketing expenses € 62.7 59.5 50.4
Increase of general and administrative expense € 13.3    
General and administrative expense (as a percent) 3.00%    
General and administrative expenses [1] € 495.0 481.7 276.8
Fair value adjustments of financial instruments measured at fair value 0.0 0.0 € 277.8
Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine      
Disclosure Of Income And Expenses [Line Items]      
Cost of sales 27.3    
Inventories 19.6 € 0.0  
Maximum | Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine      
Disclosure Of Income And Expenses [Line Items]      
Write-downs (reversals of write-downs) of inventories € 46.9    
[1]     Adjustments to prior-year figures due to change in functional allocation of general and administrative expenses and other operating expenses (see Note 7.2).